News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pulmonx, Inc. Gets FDA Nod for U.S. Trial of Emphysema Therapy


8/28/2012 10:03:02 AM

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx, an emerging leader in interventional pulmonology, announced today that the U.S. Food and Drug Administration (FDA) has approved its request for an Investigational Device Exemption (IDE) to commence a multi-center pivotal clinical trial. Pulmonx intends to use the results from this trial to support a subsequent premarket approval application (PMA) for the Zephyr® Endobronchial Valve (EBV). This new trial will incorporate the use of the Pulmonx Chartis System to plan valve treatment.

Read at BioSpace.com

comments powered by Disqus
   
Emphysema

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES